n-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2h)-carboxamide and Cardiomegaly

n-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2h)-carboxamide has been researched along with Cardiomegaly* in 1 studies

Other Studies

1 other study(ies) available for n-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2h)-carboxamide and Cardiomegaly

ArticleYear
Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice.
    Channels (Austin, Tex.), 2013, Jan-01, Volume: 7, Issue:1

    Heart failure is becoming a global epidemic. It exerts a staggering toll on quality of life, and substantial medical and economic impact. In a pre-clinical model of cardiac hypertrophy and heart failure, we were able to overcome loss of heart function by administering the TRPV1 antagonist BCTC (4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide). The results presented here identify TRPV1 antagonists as new treatment options for cardiac hypertrophy and heart failure.

    Topics: Animals; Apoptosis; Cardiomegaly; Disease Models, Animal; Heart Failure; Humans; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Natriuretic Peptide, Brain; Pyrazines; Pyridines; TRPV Cation Channels

2013